Prostate cancer vaccine - Northwest Biotherapeutics

Drug Profile

Prostate cancer vaccine - Northwest Biotherapeutics

Alternative Names: CaPVax; DC1/HRPC; DCVax-Prostate

Latest Information Update: 08 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Prostate cancer

Highest Development Phases

  • Suspended Prostate cancer

Most Recent Events

  • 08 Oct 2014 Phase-III development is still suspended
  • 04 Feb 2013 Prostate cancer vaccine - Northwest Biotherapeutics is available for licensing.
  • 04 Nov 2010 Northwest Biotherapeutics receives a Qualified Therapeutic Discovery Project grant from the US Government for DCVax® development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top